Discover how high-sugar diets contribute to more aggressive lung tumor growth — and how this knowledge could shape future ...

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 ...

A recent study reveals how the expansion and functional divergence of terpene synthase genes (TPSs) in flowering plants ...

This new cryo-EM structure represents a remarkable advance in our understanding of how human PINK1 is stabilized” said ...

Sagimet Biosciences Inc. has obtained IND clearance from the FDA for TVB-3567 (ASC-60), a selective small-molecule fatty acid ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

From cognitive enhancement to mood support and increased energy levels, methylene blue has gained popularity for its ...

Topline data were announced from a phase 3 trial investigating lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension.

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in ...

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received ...